Laurus Labs · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Analyst raised concerns about potential impact of USAID funding pauses on ARV business. Management confirmed ~20% exposure (INR 250 crore) in formulation business to US-funded programs globally but expects limited near-term impact as inquiries continue for treatment (not PrEP).
Analyst specifically questioned receivables increase. Management attributed this to longer order-to-delivery cycles for complex CDMO projects and higher logistics lead times for US/Canada formulation sales. Receivables at INR 2,000 crore vs Q4 revenue of INR 1,750 crore raised concerns.
Analyst questioned China supply chain risks and tariff impacts. Management declined to comment specifically, stating it's too early to assess. Acknowledged some partners request avoidance of certain sources but cannot fully de-risk indirect KSM/intermediate dependencies on China currently.
Asset turnover at 0.83x vs historical 1.1x suggests significant underutilization of INR 3,200 crore CapEx deployed over FY22-FY25. Management avoided committing to timeline for recovery, noting it depends on project scale and complexity progression.
